XELOX(+bevacizumab), efficacy, safety, QOL Study:FOLFOX(+bevacizumab) after starting therapy, for patients can’t continue continuous infusion therapy

ABSTRACT: Interventions: 1000mg/m2 of oral Xeloda twice daily on days 1 through 14 every 3 weeks. L-OHP 130mg/m2 is administered intravenous injection on day 1. (Bevacizumab 7.5mg/kg is administered intravenous injection on day 1.) Primary outcome(s): FOLFOX(+bevacizumab) from PFS Study Design: Single arm Non-randomized

DISEASE(S): Advanced And Recurrent Colorectal Cancer

PROVIDER: 2619416 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR